-transparent.png){kind=logo}
Aztreonam (AZT) was evaluated for its clinical efficacy in 6 patients with pelvic peritonitis. In all the cases, AZT was administered by intravenous injection, and the duration of treatment ranged from 4 to 12 days. Daily dose was 2 g in 4 cases, and 4 g in the remaining 2 cases. Surgical treatment was necessary in 2 cases, whereas in another 2 cases, either LMOX or ABPC was administered in addition to AZT. The clinical results was excellent or good in 5 out of 6 cases. Side effects possibly attributed to AZT were diarrhea in 2 cases and slight increase of GOT and GPT in 1 case, although they disappeared promptly afterward.
Related Publications
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
July 1987,
Lancet (London, England),
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
November 1985,
The Japanese journal of antibiotics,
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
January 1987,
Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
October 1901,
Texas medical journal (Austin, Tex.),
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
June 1888,
Daniel's Texas medical journal,
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
January 1999,
Ryoikibetsu shokogun shirizu,
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
October 1888,
British medical journal,
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
December 1988,
Hinyokika kiyo. Acta urologica Japonica,
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
September 1894,
The Southern medical record,
K Okamura, and
M Nakakuki, and
K Yamada, and
Y Abe, and
K Funaki
September 1946,
Bulletin. Vancouver Medical Association,
